Impact of pre-therapy viral load on virological response to modern first-line HAART
We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies. A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to lev...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2013-01, Vol.18 (7), p.867-876 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 876 |
|---|---|
| container_issue | 7 |
| container_start_page | 867 |
| container_title | Antiviral therapy |
| container_volume | 18 |
| creator | SANTORO, Maria Mercedes ARMENIA, Daniele FORBID, Federica LATINI, Alessandra PALAMARA, Guido LIBERTONE, Raffaella TOZZI, Valerio BOUMIS, Evangelo TOMMASI, Chiara PINNETTI, Carmela AMMASSARI, Adriana NICASTRI, Emanuele ALTERI, Claudia BUONOMINI, Annarita SVIEHER, Valentina ANDREONI, Massimo NARCISO, Pasquale MUSSINI, Cristina ANTINORI, Andrea CECCHERINI-SILBERSTEIN, Francesco DI PERRI, Giovanni PERNO, Carlo Federico FLANDRE, Philippe CALCAGNO, Andrea SANTORO, Mario GORI, Caterina FABENI, Lavinia BELLAGAMBA, Rita BORGHI, Vanni |
| description | We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies.
A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and > 500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤ 50 copies/ml) and on the time to virological rebound (first of two consecutive viraemia values > 50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses.
Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia > 100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was > 90% in all pre-HAART viraemia ranges, with the only exception of range > 500,000 copies/ml (virological success = 83%; P < 0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates confirmed this result: patients with pre-HAART viraemia > 500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P < 0.001). Pre-HAART viraemia > 500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P = 0.050).
At the time of modern HAART, and even though an average > 90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with > 500,000 copies/ml represent a significant population that may deserve special attention. |
| doi_str_mv | 10.3851/IMP2531 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490762010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490762010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c274t-480c031c390dbb8775b310a238acba2549bca54d8fe5c7286abe04352e54852c3</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQBuBFFFur-A9kL6KX6OxXszmWorZQUbSew2Yz0UiSjbup0H9vSqOehhkeXoaXkHMGN0Irdrt8fOZKsAMy5iAh4qD0IRkzoZJoqoQakZMQPgG4TgCOyYgLIYUCNiavy7o1tqOuoK3HqPtAb9ot_S69qWjlTE5ds9tc5d5L2988htY1AWnnaO1y9A0tSh-6qCobpIvZ7GV9So4KUwU8G-aEvN3freeLaPX0sJzPVpHlsewiqcGCYFYkkGeZjmOVCQaGC21sZriSSWaNkrkuUNmY66nJEPq3OSqpFbdiQq73ua13XxsMXVqXwWJVmQbdJqRMJhBPOTDo6dWeWu9C8FikrS9r47cpg3TXYDo02MuLIXST1Zj_ud_KenA5ABP6QgpvGluGf6chEUxr8QNoM3ak</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490762010</pqid></control><display><type>article</type><title>Impact of pre-therapy viral load on virological response to modern first-line HAART</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SANTORO, Maria Mercedes ; ARMENIA, Daniele ; FORBID, Federica ; LATINI, Alessandra ; PALAMARA, Guido ; LIBERTONE, Raffaella ; TOZZI, Valerio ; BOUMIS, Evangelo ; TOMMASI, Chiara ; PINNETTI, Carmela ; AMMASSARI, Adriana ; NICASTRI, Emanuele ; ALTERI, Claudia ; BUONOMINI, Annarita ; SVIEHER, Valentina ; ANDREONI, Massimo ; NARCISO, Pasquale ; MUSSINI, Cristina ; ANTINORI, Andrea ; CECCHERINI-SILBERSTEIN, Francesco ; DI PERRI, Giovanni ; PERNO, Carlo Federico ; FLANDRE, Philippe ; CALCAGNO, Andrea ; SANTORO, Mario ; GORI, Caterina ; FABENI, Lavinia ; BELLAGAMBA, Rita ; BORGHI, Vanni</creator><creatorcontrib>SANTORO, Maria Mercedes ; ARMENIA, Daniele ; FORBID, Federica ; LATINI, Alessandra ; PALAMARA, Guido ; LIBERTONE, Raffaella ; TOZZI, Valerio ; BOUMIS, Evangelo ; TOMMASI, Chiara ; PINNETTI, Carmela ; AMMASSARI, Adriana ; NICASTRI, Emanuele ; ALTERI, Claudia ; BUONOMINI, Annarita ; SVIEHER, Valentina ; ANDREONI, Massimo ; NARCISO, Pasquale ; MUSSINI, Cristina ; ANTINORI, Andrea ; CECCHERINI-SILBERSTEIN, Francesco ; DI PERRI, Giovanni ; PERNO, Carlo Federico ; FLANDRE, Philippe ; CALCAGNO, Andrea ; SANTORO, Mario ; GORI, Caterina ; FABENI, Lavinia ; BELLAGAMBA, Rita ; BORGHI, Vanni</creatorcontrib><description>We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies.
A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and > 500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤ 50 copies/ml) and on the time to virological rebound (first of two consecutive viraemia values > 50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses.
Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia > 100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was > 90% in all pre-HAART viraemia ranges, with the only exception of range > 500,000 copies/ml (virological success = 83%; P < 0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates confirmed this result: patients with pre-HAART viraemia > 500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P < 0.001). Pre-HAART viraemia > 500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P = 0.050).
At the time of modern HAART, and even though an average > 90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with > 500,000 copies/ml represent a significant population that may deserve special attention.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP2531</identifier><identifier>PMID: 23343501</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Female ; Genotype ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; HIV-1 - genetics ; HIV-1 - physiology ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recurrence ; Risk Factors ; Treatment Failure ; Treatment Outcome ; Viral Load ; Viremia - drug therapy ; Viremia - virology</subject><ispartof>Antiviral therapy, 2013-01, Vol.18 (7), p.867-876</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c274t-480c031c390dbb8775b310a238acba2549bca54d8fe5c7286abe04352e54852c3</citedby><cites>FETCH-LOGICAL-c274t-480c031c390dbb8775b310a238acba2549bca54d8fe5c7286abe04352e54852c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28093188$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23343501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SANTORO, Maria Mercedes</creatorcontrib><creatorcontrib>ARMENIA, Daniele</creatorcontrib><creatorcontrib>FORBID, Federica</creatorcontrib><creatorcontrib>LATINI, Alessandra</creatorcontrib><creatorcontrib>PALAMARA, Guido</creatorcontrib><creatorcontrib>LIBERTONE, Raffaella</creatorcontrib><creatorcontrib>TOZZI, Valerio</creatorcontrib><creatorcontrib>BOUMIS, Evangelo</creatorcontrib><creatorcontrib>TOMMASI, Chiara</creatorcontrib><creatorcontrib>PINNETTI, Carmela</creatorcontrib><creatorcontrib>AMMASSARI, Adriana</creatorcontrib><creatorcontrib>NICASTRI, Emanuele</creatorcontrib><creatorcontrib>ALTERI, Claudia</creatorcontrib><creatorcontrib>BUONOMINI, Annarita</creatorcontrib><creatorcontrib>SVIEHER, Valentina</creatorcontrib><creatorcontrib>ANDREONI, Massimo</creatorcontrib><creatorcontrib>NARCISO, Pasquale</creatorcontrib><creatorcontrib>MUSSINI, Cristina</creatorcontrib><creatorcontrib>ANTINORI, Andrea</creatorcontrib><creatorcontrib>CECCHERINI-SILBERSTEIN, Francesco</creatorcontrib><creatorcontrib>DI PERRI, Giovanni</creatorcontrib><creatorcontrib>PERNO, Carlo Federico</creatorcontrib><creatorcontrib>FLANDRE, Philippe</creatorcontrib><creatorcontrib>CALCAGNO, Andrea</creatorcontrib><creatorcontrib>SANTORO, Mario</creatorcontrib><creatorcontrib>GORI, Caterina</creatorcontrib><creatorcontrib>FABENI, Lavinia</creatorcontrib><creatorcontrib>BELLAGAMBA, Rita</creatorcontrib><creatorcontrib>BORGHI, Vanni</creatorcontrib><title>Impact of pre-therapy viral load on virological response to modern first-line HAART</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies.
A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and > 500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤ 50 copies/ml) and on the time to virological rebound (first of two consecutive viraemia values > 50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses.
Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia > 100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was > 90% in all pre-HAART viraemia ranges, with the only exception of range > 500,000 copies/ml (virological success = 83%; P < 0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates confirmed this result: patients with pre-HAART viraemia > 500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P < 0.001). Pre-HAART viraemia > 500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P = 0.050).
At the time of modern HAART, and even though an average > 90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with > 500,000 copies/ml represent a significant population that may deserve special attention.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Female</subject><subject>Genotype</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - physiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Viremia - drug therapy</subject><subject>Viremia - virology</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1Lw0AQBuBFFFur-A9kL6KX6OxXszmWorZQUbSew2Yz0UiSjbup0H9vSqOehhkeXoaXkHMGN0Irdrt8fOZKsAMy5iAh4qD0IRkzoZJoqoQakZMQPgG4TgCOyYgLIYUCNiavy7o1tqOuoK3HqPtAb9ot_S69qWjlTE5ds9tc5d5L2988htY1AWnnaO1y9A0tSh-6qCobpIvZ7GV9So4KUwU8G-aEvN3freeLaPX0sJzPVpHlsewiqcGCYFYkkGeZjmOVCQaGC21sZriSSWaNkrkuUNmY66nJEPq3OSqpFbdiQq73ua13XxsMXVqXwWJVmQbdJqRMJhBPOTDo6dWeWu9C8FikrS9r47cpg3TXYDo02MuLIXST1Zj_ud_KenA5ABP6QgpvGluGf6chEUxr8QNoM3ak</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>SANTORO, Maria Mercedes</creator><creator>ARMENIA, Daniele</creator><creator>FORBID, Federica</creator><creator>LATINI, Alessandra</creator><creator>PALAMARA, Guido</creator><creator>LIBERTONE, Raffaella</creator><creator>TOZZI, Valerio</creator><creator>BOUMIS, Evangelo</creator><creator>TOMMASI, Chiara</creator><creator>PINNETTI, Carmela</creator><creator>AMMASSARI, Adriana</creator><creator>NICASTRI, Emanuele</creator><creator>ALTERI, Claudia</creator><creator>BUONOMINI, Annarita</creator><creator>SVIEHER, Valentina</creator><creator>ANDREONI, Massimo</creator><creator>NARCISO, Pasquale</creator><creator>MUSSINI, Cristina</creator><creator>ANTINORI, Andrea</creator><creator>CECCHERINI-SILBERSTEIN, Francesco</creator><creator>DI PERRI, Giovanni</creator><creator>PERNO, Carlo Federico</creator><creator>FLANDRE, Philippe</creator><creator>CALCAGNO, Andrea</creator><creator>SANTORO, Mario</creator><creator>GORI, Caterina</creator><creator>FABENI, Lavinia</creator><creator>BELLAGAMBA, Rita</creator><creator>BORGHI, Vanni</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>Impact of pre-therapy viral load on virological response to modern first-line HAART</title><author>SANTORO, Maria Mercedes ; ARMENIA, Daniele ; FORBID, Federica ; LATINI, Alessandra ; PALAMARA, Guido ; LIBERTONE, Raffaella ; TOZZI, Valerio ; BOUMIS, Evangelo ; TOMMASI, Chiara ; PINNETTI, Carmela ; AMMASSARI, Adriana ; NICASTRI, Emanuele ; ALTERI, Claudia ; BUONOMINI, Annarita ; SVIEHER, Valentina ; ANDREONI, Massimo ; NARCISO, Pasquale ; MUSSINI, Cristina ; ANTINORI, Andrea ; CECCHERINI-SILBERSTEIN, Francesco ; DI PERRI, Giovanni ; PERNO, Carlo Federico ; FLANDRE, Philippe ; CALCAGNO, Andrea ; SANTORO, Mario ; GORI, Caterina ; FABENI, Lavinia ; BELLAGAMBA, Rita ; BORGHI, Vanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c274t-480c031c390dbb8775b310a238acba2549bca54d8fe5c7286abe04352e54852c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Female</topic><topic>Genotype</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - physiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Viremia - drug therapy</topic><topic>Viremia - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SANTORO, Maria Mercedes</creatorcontrib><creatorcontrib>ARMENIA, Daniele</creatorcontrib><creatorcontrib>FORBID, Federica</creatorcontrib><creatorcontrib>LATINI, Alessandra</creatorcontrib><creatorcontrib>PALAMARA, Guido</creatorcontrib><creatorcontrib>LIBERTONE, Raffaella</creatorcontrib><creatorcontrib>TOZZI, Valerio</creatorcontrib><creatorcontrib>BOUMIS, Evangelo</creatorcontrib><creatorcontrib>TOMMASI, Chiara</creatorcontrib><creatorcontrib>PINNETTI, Carmela</creatorcontrib><creatorcontrib>AMMASSARI, Adriana</creatorcontrib><creatorcontrib>NICASTRI, Emanuele</creatorcontrib><creatorcontrib>ALTERI, Claudia</creatorcontrib><creatorcontrib>BUONOMINI, Annarita</creatorcontrib><creatorcontrib>SVIEHER, Valentina</creatorcontrib><creatorcontrib>ANDREONI, Massimo</creatorcontrib><creatorcontrib>NARCISO, Pasquale</creatorcontrib><creatorcontrib>MUSSINI, Cristina</creatorcontrib><creatorcontrib>ANTINORI, Andrea</creatorcontrib><creatorcontrib>CECCHERINI-SILBERSTEIN, Francesco</creatorcontrib><creatorcontrib>DI PERRI, Giovanni</creatorcontrib><creatorcontrib>PERNO, Carlo Federico</creatorcontrib><creatorcontrib>FLANDRE, Philippe</creatorcontrib><creatorcontrib>CALCAGNO, Andrea</creatorcontrib><creatorcontrib>SANTORO, Mario</creatorcontrib><creatorcontrib>GORI, Caterina</creatorcontrib><creatorcontrib>FABENI, Lavinia</creatorcontrib><creatorcontrib>BELLAGAMBA, Rita</creatorcontrib><creatorcontrib>BORGHI, Vanni</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SANTORO, Maria Mercedes</au><au>ARMENIA, Daniele</au><au>FORBID, Federica</au><au>LATINI, Alessandra</au><au>PALAMARA, Guido</au><au>LIBERTONE, Raffaella</au><au>TOZZI, Valerio</au><au>BOUMIS, Evangelo</au><au>TOMMASI, Chiara</au><au>PINNETTI, Carmela</au><au>AMMASSARI, Adriana</au><au>NICASTRI, Emanuele</au><au>ALTERI, Claudia</au><au>BUONOMINI, Annarita</au><au>SVIEHER, Valentina</au><au>ANDREONI, Massimo</au><au>NARCISO, Pasquale</au><au>MUSSINI, Cristina</au><au>ANTINORI, Andrea</au><au>CECCHERINI-SILBERSTEIN, Francesco</au><au>DI PERRI, Giovanni</au><au>PERNO, Carlo Federico</au><au>FLANDRE, Philippe</au><au>CALCAGNO, Andrea</au><au>SANTORO, Mario</au><au>GORI, Caterina</au><au>FABENI, Lavinia</au><au>BELLAGAMBA, Rita</au><au>BORGHI, Vanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of pre-therapy viral load on virological response to modern first-line HAART</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>18</volume><issue>7</issue><spage>867</spage><epage>876</epage><pages>867-876</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies.
A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and > 500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤ 50 copies/ml) and on the time to virological rebound (first of two consecutive viraemia values > 50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses.
Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia > 100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was > 90% in all pre-HAART viraemia ranges, with the only exception of range > 500,000 copies/ml (virological success = 83%; P < 0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates confirmed this result: patients with pre-HAART viraemia > 500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P < 0.001). Pre-HAART viraemia > 500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P = 0.050).
At the time of modern HAART, and even though an average > 90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with > 500,000 copies/ml represent a significant population that may deserve special attention.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>23343501</pmid><doi>10.3851/IMP2531</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2013-01, Vol.18 (7), p.867-876 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1490762010 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Female Genotype HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV-1 - genetics HIV-1 - physiology Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Recurrence Risk Factors Treatment Failure Treatment Outcome Viral Load Viremia - drug therapy Viremia - virology |
| title | Impact of pre-therapy viral load on virological response to modern first-line HAART |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T21%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20pre-therapy%20viral%20load%20on%20virological%20response%20to%20modern%20first-line%20HAART&rft.jtitle=Antiviral%20therapy&rft.au=SANTORO,%20Maria%20Mercedes&rft.date=2013-01-01&rft.volume=18&rft.issue=7&rft.spage=867&rft.epage=876&rft.pages=867-876&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP2531&rft_dat=%3Cproquest_cross%3E1490762010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490762010&rft_id=info:pmid/23343501&rfr_iscdi=true |